SUZHOU, China, Dec. 30,
2024 /PRNewswire/ -- Hangzhou Sino-US Huadong
Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of
Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech
(Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have
reached a strategic cooperation. The two parties will jointly
develop the small nucleic acid (siRNA) drug SNK-2726, targeting
angiotensinogen (AGT) for the treatment of hypertension.
Huadong Medicine has obtained the
exclusive option, once exercised, for the right to develop,
register, manufacture and commercialize the drug in Greater China.
SynerK owns intellectual property rights of SNK-2726, which is
currently in the IND filing preparation stage. According to the
agreement, the two parties will jointly develop SNK-2726 to a
certain stage. At the same time, Huadong
Medicine obtains the exclusive option and may pay the
exercise fee in the future to obtain the rights for exclusive
development, registration, production and commercialization of
SNK-2726 in Greater China. After
Huadong Medicine exercises its
rights, SynerK will also be entitled to receive subsequent R&D
milestones and sales milestones, as well as tiered loyalties based
on net sales after commercialization.
Dr. Tao Lan, CEO of SynerK, said: "We are very excited about the
opportunity to cooperate with Huadong
Medicine. Huadong Medicine's
corporate philosophy of 'scientific research-based and
patient-centered' coincides with our mission of 'changing patients'
lives.' This cooperation further demonstrates the potential of
SynerK's GalNexus siRNA platform. Through this 1+1>2
collaborative effort, we expect to accelerate the development of
SNK-2726 and bring new treatment options to patients."
Lv Liang, chairman and general manager of Huadong Medicine, said: "We are very pleased to
reach this strategic cooperation with SynerK to develop the
innovative siRNA drug SNK-2726 together. SynerK has novel nucleic
acid drug technology platforms with independent intellectual
property rights. Huadong Medicine
will use its deep accumulation in innovative drug research and
development and rich experience in clinical and commercialization
of drugs in the cardiovascular field. Through close cooperation
with SynerK, we will jointly accelerate the development of SNK-2726
and benefit more hypertensive patients as soon as possible."
About SNK-2726
SNK-2726, with independent intellectual property rights owned by
SynerK, is a subcutaneous RNAi drug targeting angiotensinogen
(AGT). It is being developed for the treatment of hypertension and
is currently in the IND application preparation stage. AGT is the
upstream precursor in the renin-angiotensin-aldosterone system
(RAAS). AGT in the blood circulation is produced mainly by the
liver. Inhibiting the production of AGT can effectively block the
activity of the RAAS system and reduce blood pressure. Preclinical
study results showed that SNK-2726 can potently inhibit the
synthesis of AGT in the liver and has prolonged effects, which can
lead to a stable and continuous decrease of AGT, and ultimately
lower blood pressure.
About SynerK
SynerK is a biopharmaceutical company focusing on the
development of RNA-targeted therapies. It operates in the
USA (Boston, MA) and China (Suzhou and Beijing). The cofounders are industry experts
with rich experience in nucleic acid drug discovery and
development. SynerK aims to build a world-class RNA-targeted
therapeutic company by developing products that have the potential
to be first-in-class or best-in-class treatments, targeting
diseases that are difficult to cure with existing therapies.
For more information, please visit: www.synerk.cn
About Huadong Medicine Co., Ltd.
Huadong Medicine Co., Ltd. (stock code: 000963.SZ) was founded
in 1993 and is headquartered in Hangzhou, Zhejiang. The company adheres to the corporate
philosophy of " scientific research-based and
patient-centered." After more than 30 years of development, the
company's business covers the entire pharmaceutical industry chain,
with four major business segments: pharmaceutical industry,
pharmaceutical business, aesthetic medicine, and industrial
microbiology. It has developed into a listed, large-scale
comprehensive pharmaceutical company integrating innovative
pharmaceutical research and development, production, and
distribution. In 2023, the company achieved operating income of
40.624 billion yuan, with more than
10,000 employees, and has extensive commercial coverage and
marketing capabilities.
For more information, please visit
www.eastchinapharm.com
View original
content:https://www.prnewswire.com/news-releases/huadong-medicine-co-ltd-and-synerk-reached-a-strategic-cooperation-to-jointly-develop-a-novel-sirna-drug-snk-2726-302340021.html
SOURCE SynerK
